Physician profile
Daniel Bonner
NPI 1720755192
$6,221.78
in general payments reported to CMS, 2019-2025
27 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.29 · 2022: $1,976 · 2023: $1,337 · 2024: $1,536 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,171.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,186.71 | 2022-2024 | Cardiomems |
| Amgen INC. | $651.07 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $589.37 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.17 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $474.27 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $443.72 | 2023-2025 | Farxiga, Lokelma, Wainua |
| Novartis Pharmaceuticals Corporation | $440.67 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $404.66 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $313.50 | 2023-2025 | Lifevest |
| Cvrx, INC. | $232.79 | 2024-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $213.23 | 2022-2024 | Onpattro, Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $161.98 | 2022-2025 | |
| Novo Nordisk INC | $104.18 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $83.50 | 2021-2025 | Nexletol |
| Abiomed | $78.30 | 2024 | Impella |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $68.80 | 2022 | |
| Bridgebio Pharma, INC. | $67.02 | 2025 | Attruby |
| Scpharmaceuticals INC. | $48.65 | 2023-2025 | |
| Itamar Medical INC | $32.81 | 2022 | |
| Amarin Pharma, INC. | $22.17 | 2022 | |
| Vital Connect, INC | $21.47 | 2025 | Vitalpatch Rtm |
| Arbor Pharmaceuticals, INC. | $19.64 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.45 | 2023 | Inpefa |
| Philips North America LLC | $15.07 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.75 | 2023 | Livalo |
| Actelion Pharmaceuticals US, INC. | $14.72 | 2021 | |
| Chiesi USA, INC. | $14.11 | 2025 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.